DE69836729D1 - Anti-vefg antibodies - Google Patents

Anti-vefg antibodies

Info

Publication number: DE69836729D1
Authority: DE; Germany
Prior art keywords: antibodies; vegf; vefg; vitro; vegf antibodies
Prior art date: 1997-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69836729T

Other languages

English (en)

Other versions

DE69836729T2 (de

Inventor

Manuel Baca

A Wells

G Presta

B Lowman

Man-Yee Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-07

Filing date

1998-04-03

Publication date

2007-02-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69836729(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-06 Priority claimed from US08/908,469 external-priority patent/US6884879B1/en

1998-04-03 Application filed by Genentech Inc filed Critical Genentech Inc

2007-02-08 Publication of DE69836729D1 publication Critical patent/DE69836729D1/de

2007-12-13 Application granted granted Critical

2007-12-13 Publication of DE69836729T2 publication Critical patent/DE69836729T2/de

2018-04-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Air Bags (AREA)
Steering Control In Accordance With Driving Conditions (AREA)

DE69836729T 1997-04-07 1998-04-03 Anti-vefg antibodies Expired - Lifetime DE69836729T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US83350497A	1997-04-07	1997-04-07
US833504		1997-04-07
US908469		1997-08-06
US08/908,469 US6884879B1 (en)	1997-04-07	1997-08-06	Anti-VEGF antibodies
PCT/US1998/006604 WO1998045331A2 (en)	1997-04-07	1998-04-03	Anti-vegf antibodies

Publications (2)

Publication Number	Publication Date
DE69836729D1 true DE69836729D1 (de)	2007-02-08
DE69836729T2 DE69836729T2 (de)	2007-12-13

Family

ID=27125626

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DE200712000021 Pending DE122007000021I1 (de)	1997-04-07	1998-04-03	Anti-vefg Antibodies
DE200512000026 Pending DE122005000026I1 (de)	1997-04-07	1998-04-03	Anti-VEGF Antik¦rper.
DE69836729T Expired - Lifetime DE69836729T2 (de)	1997-04-07	1998-04-03	Anti-vefg antibodies
DE69829891T Expired - Lifetime DE69829891T2 (de)	1997-04-07	1998-04-03	Anti-VEGF Antikörper
DE200512000050 Pending DE122005000050I1 (de)	1997-04-07	2005-05-25	Anti-Vegf Antik¦rper.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE200712000021 Pending DE122007000021I1 (de)	1997-04-07	1998-04-03	Anti-vefg Antibodies
DE200512000026 Pending DE122005000026I1 (de)	1997-04-07	1998-04-03	Anti-VEGF Antik¦rper.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69829891T Expired - Lifetime DE69829891T2 (de)	1997-04-07	1998-04-03	Anti-VEGF Antikörper
DE200512000050 Pending DE122005000050I1 (de)	1997-04-07	2005-05-25	Anti-Vegf Antik¦rper.

Country Status (26)

Country	Link
US (2)	US7060269B1 (de)
EP (4)	EP1325932B9 (de)
JP (1)	JP3957765B2 (de)
KR (2)	KR100816621B1 (de)
CN (1)	CN100480269C (de)
AT (2)	ATE349470T1 (de)
AU (1)	AU743758B2 (de)
BR (1)	BRPI9809387B8 (de)
CA (1)	CA2286330C (de)
CY (3)	CY2005008I2 (de)
DE (5)	DE122007000021I1 (de)
DK (2)	DK1325932T5 (de)
ES (2)	ES2236634T3 (de)
FR (2)	FR05C0020I2 (de)
GE (1)	GEP20105118B (de)
HK (2)	HK1084402A1 (de)
IL (1)	IL132240A0 (de)
LT (1)	LTPA2005005I1 (de)
LU (2)	LU91167I2 (de)
NL (2)	NL300193I2 (de)
NO (3)	NO324264B1 (de)
NZ (1)	NZ500078A (de)
PT (1)	PT1325932E (de)
SI (1)	SI1325932T1 (de)
TR (1)	TR199903123T2 (de)
WO (1)	WO1998045331A2 (de)

Families Citing this family (503)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US6740506B2 (en)	1995-12-07	2004-05-25	Diversa Corporation	End selection in directed evolution
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
US6562594B1 (en)	1999-09-29	2003-05-13	Diversa Corporation	Saturation mutagenesis in directed evolution
US6939689B2 (en)	1995-12-07	2005-09-06	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6352842B1 (en)	1995-12-07	2002-03-05	Diversa Corporation	Exonucease-mediated gene assembly in directed evolution
US6713279B1 (en)	1995-12-07	2004-03-30	Diversa Corporation	Non-stochastic generation of genetic vaccines and enzymes
US6238884B1 (en)	1995-12-07	2001-05-29	Diversa Corporation	End selection in directed evolution
US5830696A (en)	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
US6358709B1 (en)	1995-12-07	2002-03-19	Diversa Corporation	End selection in directed evolution
US6171820B1 (en) *	1995-12-07	2001-01-09	Diversa Corporation	Saturation mutagenesis in directed evolution
US6361974B1 (en)	1995-12-07	2002-03-26	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US7371376B1 (en)	1996-10-18	2008-05-13	Genentech, Inc.	Anti-ErbB2 antibodies
US7122636B1 (en)	1997-02-21	2006-10-17	Genentech, Inc.	Antibody fragment-polymer conjugates and uses of same
JP3521382B2 (ja)	1997-02-27	2004-04-19	日本たばこ産業株式会社	細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en)	1997-02-27	2006-09-26	Japan Tobacco, Inc.	JTT-1 protein and methods of inhibiting lymphocyte activation
US20020032315A1 (en) *	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
KR100816621B1 (ko)	1997-04-07	2008-03-24	제넨테크, 인크.	항-ｖｅｇｆ 항체
US20070059302A1 (en) *	1997-04-07	2007-03-15	Genentech, Inc.	Anti-vegf antibodies
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US6887674B1 (en)	1998-04-13	2005-05-03	California Institute Of Technology	Artery- and vein-specific proteins and uses therefor
US6864227B1 (en)	1998-04-13	2005-03-08	California Institute Of Technology	Artery-and vein-specific proteins and uses therefor
WO2000029584A1 (en) *	1998-11-18	2000-05-25	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
EP1950300A3 (de)	1998-11-18	2011-03-23	Genentech, Inc.	Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
WO2000034337A1 (en) *	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
CA2355976C (en) *	1998-12-22	2012-07-17	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
CN101073668A (zh)	1999-04-28	2007-11-21	德克萨斯大学董事会	用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
JP2003508027A (ja) *	1999-07-29	2003-03-04	ダイアックスコーポレイション	フィブリン結合性部分
JP4210454B2 (ja)	2001-03-27	2009-01-21	日本たばこ産業株式会社	炎症性腸疾患治療剤
JP3871503B2 (ja)	1999-08-30	2007-01-24	日本たばこ産業株式会社	免疫性疾患治療剤
EP1757701A1 (de)	1999-12-24	2007-02-28	Genentech, Inc.	Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
ES2270893T3 (es)	1999-12-24	2007-04-16	Genentech, Inc.	Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (ja)	2000-05-18	2004-12-02	日本たばこ産業株式会社	副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP2075253A1 (de)	2000-06-23	2009-07-01	Genentech, Inc.	Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
DK2042597T3 (da)	2000-06-23	2014-08-11	Genentech Inc	Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
US6902718B2 (en)	2000-10-24	2005-06-07	Diatide, Inc.	Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
US6989138B2 (en)	2000-10-24	2006-01-24	Diatide, Inc.	Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
JP4212278B2 (ja)	2001-03-01	2009-01-21	日本たばこ産業株式会社	移植片拒絶反応抑制剤
US7117096B2 (en)	2001-04-17	2006-10-03	Abmaxis, Inc.	Structure-based selection and affinity maturation of antibody library
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
TWI284539B (en)	2001-07-30	2007-08-01	Epix Pharm Inc	A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US20050123925A1 (en)	2002-11-15	2005-06-09	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
KR100988949B1 (ko) *	2001-10-25	2010-10-20	제넨테크, 인크.	당단백질 조성물
US20030190705A1 (en) *	2001-10-29	2003-10-09	Sunol Molecular Corporation	Method of humanizing immune system molecules
DE60325334D1 (de)	2002-02-05	2009-01-29	Genentech Inc	Proteinaufreinigung
US7497827B2 (en)	2004-07-13	2009-03-03	Dexcom, Inc.	Transcutaneous analyte sensor
US10022078B2 (en)	2004-07-13	2018-07-17	Dexcom, Inc.	Analyte sensor
WO2003102132A2 (en)	2002-04-26	2003-12-11	Genetech, Inc.	Non-affinity purification of proteins
MXPA04011624A (es) *	2002-05-24	2005-03-07	Schering Corp	Anticuerpo neutralizante humano anti-igfr.
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en)	2002-06-28	2015-05-12	Domantis Limited	Antagonists against TNFR1 and methods of use therefor
MX337052B (es)	2002-07-15	2016-02-11	Univ Texas	Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
CN100480260C (zh)	2002-07-18	2009-04-22	克鲁塞尔荷兰公司	抗体混合物的重组生产
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
US7575893B2 (en)	2003-01-23	2009-08-18	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2192172B1 (de)	2003-02-03	2014-12-03	iBio, Inc.	System zur Expression von Genen in Pflanzen
WO2004080425A2 (en)	2003-03-12	2004-09-23	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en)	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
CN101274098A (zh) *	2003-05-30	2008-10-01	健泰科生物技术公司	利用抗-vegf抗体的治疗
SI1648940T1 (sl)	2003-07-28	2016-08-31	Genentech, Inc.	Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
AU2004261980A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody CDR polypeptide sequences with restricted diversity
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US7920906B2 (en)	2005-03-10	2011-04-05	Dexcom, Inc.	System and methods for processing analyte sensor data for sensor calibration
CN1934255B (zh)	2003-08-27	2012-07-11	奥普索特克公司	用于治疗眼新血管疾病的组合治疗
FR2859725B1 (fr) *	2003-09-16	2006-03-10	Neovacs	Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US9247900B2 (en)	2004-07-13	2016-02-02	Dexcom, Inc.	Analyte sensor
ES2646560T3 (es)	2004-01-20	2017-12-14	Merus N.V.	Mezclas de proteínas de unión
US20060122377A1 (en)	2004-02-19	2006-06-08	Genentech, Inc.	CDR-repaired antibodies
KR20120123619A (ko)	2004-03-12	2012-11-08	바스진 테라퓨틱스, 인크.	혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
EP2287194B1 (de)	2004-03-12	2016-10-26	Vasgene Therapeutics, Inc.	EphB4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
AU2005250216B2 (en)	2004-06-01	2009-12-10	Domantis Limited	Bispecific fusion antibodies with enhanced serum half-life
US8604185B2 (en)	2004-07-20	2013-12-10	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
RU2392966C2 (ru) *	2004-07-20	2010-06-27	Дженентек, Инк.	Ингибиторы ангиопоэтинподобного белка 4, их комбинации и применение
ES2531155T3 (es)	2004-07-23	2015-03-11	Genentech Inc	Cristalización de anticuerpos anti-VEGF
US7662926B2 (en)	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en)	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006034455A2 (en)	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Polipeptide compounds for inhibiting angiogenesis and tumor growth
RS52539B (en) *	2004-10-21	2013-04-30	Genentech Inc.	METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES
SG176509A1 (en)	2004-12-22	2011-12-29	Genentech Inc	Methods for producing soluble multi-membrane-spanning proteins
EP1833512A1 (de) *	2005-01-06	2007-09-19	GE Healthcare AS	Optische bilddarstellung
US20070166388A1 (en)	2005-02-18	2007-07-19	Desai Neil P	Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
CN101160123B (zh)	2005-02-18	2013-07-17	阿布拉科斯生物科学有限公司	治疗剂的组合
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
PL1861116T3 (pl)	2005-03-25	2016-02-29	Regeneron Pharma	Formulacje antagonistów VEGF
MX2007012896A (es) *	2005-04-15	2007-12-10	Schering Corp	Metodos y composiciones para tratamiento o prevencion de cancer.
JP2008543449A (ja) *	2005-06-17	2008-12-04	アボット・ラボラトリーズ	変性脊椎疾患の改良型治療方法
KR20100084706A (ko) *	2005-06-20	2010-07-27	제넨테크, 인크.	종양의 진단 및 치료를 위한 조성물 및 방법
USRE47223E1 (en)	2005-06-20	2019-02-05	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
JP2009502207A (ja)	2005-08-03	2009-01-29	フラウンホーファーユーエスエー，インコーポレイテッド	イムノグロブリンの産生のための組成物および方法
HUE042678T2 (hu)	2005-08-31	2019-07-29	Abraxis Bioscience Llc	Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
KR100877824B1 (ko)	2005-11-11	2009-01-12	한국생명공학연구원	Ｅ2ｅｐｆｕｃｐ-ｖｈｌ 상호작용 및 그 용도
JP5199108B2 (ja) *	2005-11-14	2013-05-15	ユニヴァーシティーオブサザンカリフォルニア	インテグリン結合小分子
JP2009518024A (ja) *	2005-12-06	2009-05-07	ドマンティスリミテッド	Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
DK1962895T3 (da) †	2005-12-16	2013-03-04	Regeneron Pharma	TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
EP3156418A1 (de)	2006-01-05	2017-04-19	Genentech, Inc.	Anti-ephb4-antikörper sowie verfahren zu deren verwendung
EP1976884B1 (de)	2006-01-20	2012-12-19	Genentech, Inc.	Anti-ephrinb2-antikörper sowie verfahren zu ihrer verwendung
EP1984405A4 (de)	2006-02-13	2010-06-30	Fraunhofer Usa Inc	Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
UA100969C2 (uk)	2006-03-21	2013-02-25	Дженентек, Інк.	Антитіло, яке специфічно зв'язує людський альфа5бета1 (alpha5beta1)
TW200812615A (en) *	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
UA95797C2 (ru) *	2006-03-22	2011-09-12	Ф. Хоффманн-Ля Рош Аг	Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
CA2647430A1 (en) *	2006-03-29	2007-10-11	Genentech, Inc.	Diagnostics and treatments for tumors
EP3252079B8 (de)	2006-04-07	2020-09-09	Aerpio Therapeutics LLC	An die humane proteintyrosinphosphatase-beta (hptp-beta) bindende antikörper und anwendungen davon
JP2009539384A (ja)	2006-06-06	2009-11-19	ジェネンテック・インコーポレーテッド	抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
SG172687A1 (en) *	2006-06-06	2011-07-28	Genentech Inc	Compositions and methods for modulating vascular development
PT2364691E (pt)	2006-06-16	2013-05-15	Regeneron Pharma	Formulações antagonistas de vegf adequadas para administração intravitreal
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008011513A2 (en)	2006-07-19	2008-01-24	The Cleveland Clinic Foundation	Compounds and methods of modulating angiogenesis
CN100448892C (zh) *	2006-08-02	2009-01-07	中国人民解放军军事医学科学院基础医学研究所	抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
JP2010501498A (ja)	2006-08-21	2010-01-21	エフ．ホフマン−ラロシュアーゲー	抗ｖｅｇｆ抗体による腫瘍治療
EP2562188A3 (de)	2006-09-29	2013-03-06	OncoMed Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs
US20080227119A1 (en)	2006-10-04	2008-09-18	Genentech, Inc.	ELISA for VEGF
CA2666974A1 (en) *	2006-10-20	2008-11-06	Schering Corporation	Fully human anti-vegf antibodies and methods of using
HUE029445T2 (en) *	2006-12-19	2017-02-28	Genentech Inc	VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
US20100267933A1 (en)	2006-12-21	2010-10-21	Moya Wilson	Purification of proteins
US8569464B2 (en)	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
US8362217B2 (en)	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
ES2374330T3 (es)	2007-01-22	2012-02-15	Genentech, Inc.	Precipitación con polielectrolito y purificación de anticuerpos.
US20100119526A1 (en) *	2007-01-26	2010-05-13	Bioinvent International Ab	DLL4 Signaling Inhibitors and Uses Thereof
EP2468776A3 (de)	2007-02-09	2012-11-14	Genentech, Inc.	Antikörper gegen Robo4 und Anwendungen davon
EP2136831B1 (de)	2007-03-02	2012-09-12	The Cleveland Clinic Foundation	Anti-angiogene peptide
EP2144628B1 (de)	2007-05-08	2012-10-17	Genentech, Inc.	Cystein-manipulierte anti-muc16-antikörper und antikörper-wirkstoff-konjugate
AU2007353778B9 (en)	2007-05-17	2014-04-03	Genentech, Inc.	Inhibition of tumor metastasis by anti neuropilin 2 antibodies
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN119241636A (zh)	2007-07-09	2025-01-03	健泰科生物技术公司	在多肽的重组生产期间防止二硫键还原
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
WO2009023185A1 (en)	2007-08-13	2009-02-19	Vasgene Therapeutics, Inc.	Cancer treatment using humanized antibodies that bind to ephb4
CA2697032C (en)	2007-08-22	2021-09-14	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
CN101889025B (zh)	2007-10-30	2013-11-13	健泰科生物技术公司	通过阳离子交换层析进行的抗体纯化
CA2703099A1 (en) *	2007-11-09	2009-05-14	Genentech, Inc.	Activin receptor-like kinase-i compositions and methods of use
DK2219672T3 (en)	2007-11-09	2016-05-17	Peregrine Pharmaceuticals Inc	The anti-VEGF antibody compositions and methods
TWI580694B (zh)	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
MY184496A (en)	2008-03-18	2021-04-01	Genentech Inc	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2274008B1 (de) *	2008-03-27	2014-02-26	ZymoGenetics, Inc.	Zusammensetzungen und verfahren zur hemmung von pdgfrbeta und vegf-a
WO2009129538A2 (en) *	2008-04-18	2009-10-22	Xencor, Inc.	Human equivalent monoclonal antibodies engineered from nonhuman variable regions
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
CN102112494A (zh)	2008-06-03	2011-06-29	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
NZ589434A (en)	2008-06-03	2012-11-30	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US8999702B2 (en)	2008-06-11	2015-04-07	Emd Millipore Corporation	Stirred tank bioreactor
KR102296443B1 (ko)	2008-06-25	2021-09-01	노바르티스 아게	Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
US8822645B2 (en) *	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US20100029491A1 (en) *	2008-07-11	2010-02-04	Maike Schmidt	Methods and compositions for diagnostic use for tumor treatment
WO2010010153A1 (en)	2008-07-23	2010-01-28	F. Hoffmann-La Roche Ag	Identification of subjects being susceptible to anti-angiogenesis therapy
BRPI0823046B1 (pt)	2008-08-14	2021-12-14	Genentech, Inc	Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
AR073231A1 (es) *	2008-08-29	2010-10-20	Genentech Inc	Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
JP2012502030A (ja)	2008-09-05	2012-01-26	デュークユニバーシティー	抗脂質抗体
US20100068210A1 (en)	2008-09-10	2010-03-18	Ji Junyan A	Compositions and methods for the prevention of oxidative degradation of proteins
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
AR073829A1 (es)	2008-10-14	2010-12-01	Genentech Inc	Variantes de inmunoglobulinas y sus usos.
CN107011425B (zh)	2008-11-03	2021-01-01	分子组合公司	抑制vegf-a受体相互作用的结合蛋白
ES2498274T3 (es)	2008-11-05	2014-09-24	Genentech, Inc.	Polimorfismos genéticos en degeneración macular relacionada con la edad
DK2361085T4 (en)	2008-11-22	2018-10-08	Hoffmann La Roche	USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
SG171764A1 (en)	2008-12-16	2011-07-28	Millipore Corp	Purification of proteins
SG171446A1 (en)	2008-12-16	2011-07-28	Millipore Corp	Stirred tank reactor and method
MX2011006875A (es)	2008-12-23	2011-07-20	Genentech Inc	Metodos y composiciones para uso en diagnostico de pacientes con cancer.
AU2010203353B2 (en)	2009-01-12	2016-06-16	Cytomx Therapeutics, Inc	Modified antibody compositions, methods of making and using thereof
WO2010081838A2 (en)	2009-01-14	2010-07-22	Novartis Ag	Sterile prefilled container
CN102333544A (zh)	2009-02-06	2012-01-25	通用医疗公司	治疗血管损伤的方法
EP2398494A4 (de)	2009-02-23	2015-10-28	Cytomx Therapeutics Inc	Proproteine und anwendungsverfahren dafür
JP5713923B2 (ja)	2009-02-27	2015-05-07	ジェネンテック，インコーポレイテッド	タンパク質標識方法及び組成物
JP5725563B2 (ja)	2009-03-13	2015-05-27	アブラクシスバイオサイエンス，エルエルシー	チオコルヒチン誘導体との組み合わせ療法
WO2010111254A1 (en)	2009-03-25	2010-09-30	Genentech, Inc.	Novel anti-alpha5beta1 antibodies and uses thereof
JP5501439B2 (ja)	2009-04-02	2014-05-21	ロシュグリクアートアクチェンゲゼルシャフト	完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
EP2417156B1 (de)	2009-04-07	2015-02-11	Roche Glycart AG	Trivalente, bispezifische antikörper
RU2595379C2 (ru) *	2009-04-16	2016-08-27	АббВай Биотерапеутикс Инк.	АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CA2759030A1 (en) *	2009-04-20	2010-10-28	Genentech, Inc.	Adjuvant cancer therapy
US9067986B2 (en)	2009-04-27	2015-06-30	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
EP2427479B1 (de)	2009-05-07	2018-11-21	The Regents of The University of California	Antikörper und verfahren zu ihrer verwendung
CA2665956A1 (en) *	2009-05-07	2010-11-07	Samir Patel	Combination treatment for ocular diseases
CN102459338A (zh)	2009-05-08	2012-05-16	霍夫曼-拉罗奇有限公司	人源化抗egfl7抗体及其使用方法
EP3320920A1 (de)	2009-05-08	2018-05-16	Vaccinex, Inc.	Anti-cd100-antikörper und verfahren zur verwendung davon
WO2010145846A1 (en)	2009-06-15	2010-12-23	Bayer Bioscience N.V.	Nicotiana benthamiana plants deficient in xylosyltransferase activity
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
JP6095367B2 (ja)	2009-07-13	2017-03-15	ジェネンテック，インコーポレイテッド	癌治療のための診断方法および組成物
AR078060A1 (es)	2009-07-14	2011-10-12	Novartis Ag	Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
WO2011014457A1 (en)	2009-07-27	2011-02-03	Genentech, Inc.	Combination treatments
CN102498129B (zh)	2009-07-31	2016-03-02	霍夫曼-拉罗奇有限公司	使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
KR20180010324A (ko)	2009-08-11	2018-01-30	제넨테크, 인크.	글루타민-비함유 세포 배양 배지에서의 단백질의 생성
CA2770321A1 (en)	2009-08-14	2011-02-17	Genentech, Inc.	Biological markers for monitoring patient response to vegf antagonists
MX336476B (es)	2009-08-15	2016-01-20	Genentech Inc	Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
JP5787891B2 (ja)	2009-09-01	2015-09-30	ジェネンテック，インコーポレイテッド	改変されたプロテインａ溶離による向上したタンパク質精製
US8642515B2 (en)	2009-09-04	2014-02-04	University Of Louisville Research Foundation, Inc.	Genetic determinants of prostate cancer risk
RU2012114094A (ru)	2009-09-11	2013-10-20	Дженентек, Инк.	Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
SG179196A1 (en)	2009-09-16	2012-04-27	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
CN102612566B (zh)	2009-09-17	2016-02-17	霍夫曼-拉罗奇有限公司	用于癌症患者中诊断学用途的方法和组合物
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
DK2488204T3 (en)	2009-10-16	2016-06-06	Oncomed Pharm Inc	Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
NO2491134T3 (de)	2009-10-21	2018-01-06
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
TWI505836B (zh)	2009-12-11	2015-11-01	Genentech Inc	抗－ｖｅｇｆ－ｃ抗體及其使用方法
US8765432B2 (en)	2009-12-18	2014-07-01	Oligasis, Llc	Targeted drug phosphorylcholine polymer conjugates
CN107095846A (zh)	2009-12-21	2017-08-29	霍夫曼-拉罗奇有限公司	抗体配制剂
TW201130971A (en)	2009-12-23	2011-09-16	Genentech Inc	Anti-Bv8 antibodies and uses thereof
WO2011090719A2 (en)	2009-12-29	2011-07-28	Dr. Reddy's Laboratories Ltd.	Protein purification by ion exchange
EP2531592A1 (de)	2010-02-04	2012-12-12	Vivalis	Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
AR080244A1 (es)	2010-02-23	2012-03-21	Genentech Inc	Terapia anti-angiogenesis para el tratamiento del cancer ovarico
MX354867B (es)	2010-03-22	2018-03-23	Genentech Inc Star	Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
TWI426920B (zh)	2010-03-26	2014-02-21	Hoffmann La Roche	雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
NZ602635A (en)	2010-03-29	2014-12-24	Abraxis Bioscience Llc	Methods of enhancing drug delivery and effectiveness of therapeutic agents
RU2016119999A (ru)	2010-03-29	2018-11-08	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	Способы лечения онкологических заболеваний
US20130156755A1 (en)	2010-04-19	2013-06-20	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
TWI510246B (zh)	2010-04-30	2015-12-01	Molecular Partners Ag	抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
JP2013525484A (ja)	2010-05-03	2013-06-20	ジェネンテック，インコーポレイテッド	タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
SG10201804385YA (en)	2010-05-17	2018-06-28	Emd Millipore Corp	Stimulus responsive polymers for the purification of biomolecules
SI2576580T1 (sl)	2010-05-28	2016-12-30	F. Hoffmann-La Roche Ag	Znižanje nivoja laktata in zvišanje produkcije polipeptida z znižanjem ravni izražanja laktat-dehidrogenaze in piruvat-dehidrogenaza-kinaze
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
WO2011153010A1 (en)	2010-06-04	2011-12-08	Abraxis Biosciences, Llc	Methods of treatment of pancreatic cancer
SI2585045T1 (sl)	2010-06-24	2019-11-29	Hoffmann La Roche	Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
US20120070428A1 (en) *	2010-07-02	2012-03-22	Genentech, Inc.	Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
WO2012006503A1 (en)	2010-07-09	2012-01-12	Genentech, Inc.	Anti-neuropilin antibodies and methods of use
CN103109189A (zh)	2010-07-19	2013-05-15	霍夫曼-拉罗奇有限公司	鉴定响应抗癌疗法的可能性升高的患者的方法
JP2013537522A (ja)	2010-07-19	2013-10-03	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	抗癌治療への応答可能性の増大した患者を同定する方法
RU2013109275A (ru)	2010-08-03	2014-09-10	Эббви Инк.	Иммуноглобулины с двумя вариабельными доменами и их применение
KR20130100125A (ko)	2010-08-13	2013-09-09	제넨테크, 인크.	질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
TW201208703A (en)	2010-08-17	2012-03-01	Roche Glycart Ag	Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
RU2013110875A (ru)	2010-08-24	2014-09-27	Ф.Хоффманн-Ля Рош Аг	БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
CA2809433A1 (en)	2010-08-26	2012-03-01	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
CN103347514B (zh)	2010-11-15	2017-02-08	戊瑞治疗有限公司	Fgfr1胞外域组合疗法
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
WO2012095514A1 (en)	2011-01-14	2012-07-19	Vivalis	Recombinant protein production system
BR112013020338A2 (pt)	2011-02-28	2016-10-18	Hoffmann La Roche	proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
CA2825081A1 (en)	2011-02-28	2012-09-07	Birgit Bossenmaier	Antigen binding proteins
CA2830349C (en)	2011-03-17	2019-07-16	The University Of Birmingham	Re-directed immunotherapy
SI2691417T1 (sl)	2011-03-29	2018-11-30	Roche Glycart Ag	FC variante protitelesa
CN104586861A (zh)	2011-04-01	2015-05-06	基因泰克公司	Akt抑制剂化合物和阿比特龙的组合及使用方法
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
EP2699590B8 (de)	2011-04-20	2019-04-17	Acceleron Pharma Inc.	Endoglinpolypeptide und ihre verwendung
EP2704735A1 (de)	2011-05-03	2014-03-12	Genentech, Inc.	Vaskuläre disruptoren und ihre verwendung
WO2012172054A1 (en)	2011-06-16	2012-12-20	Scil Proteins Gmbh	Modified multimeric ubiquitin proteins binding vegf-a
RU2013155695A (ru)	2011-06-30	2015-08-10	Дженентек, Инк.	Препараты антител против с-мет
US9057728B2 (en)	2011-07-12	2015-06-16	Epitomics, Inc.	FACS-based method for obtaining an antibody sequence
EP2551348B1 (de)	2011-07-29	2014-09-24	Icon Genetics GmbH	Produktion von galactosylierten N-Glycanen in Pflanzen
CA2842481A1 (en)	2011-08-17	2013-02-21	Genentech, Inc.	Inhibition of angiogenesis in refractory tumors
MX361712B (es)	2011-09-23	2018-12-14	Oncomed Pharm Inc	Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dell4) y usos de los mismos.
US10196664B2 (en)	2011-10-04	2019-02-05	Icon Genetics Gmbh	Nicotiana benthamiana plants deficient in fucosyltransferase activity
PT2766093T (pt)	2011-10-11	2018-05-18	Vaccinex Inc	Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica
JP2014532072A (ja) *	2011-10-13	2014-12-04	エアピオセラピューティックス，インコーポレイテッド	眼疾患の治療
EP2766043A4 (de)	2011-10-13	2015-06-10	Aerpio Therapeutics Inc	Verfahren zur behandlung von kapillarlecksyndrom und krebs
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
US9988424B2 (en)	2011-12-05	2018-06-05	Duke University	Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
US8790652B2 (en)	2011-12-06	2014-07-29	Vaccinex, Inc.	Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
AU2012355356B2 (en)	2011-12-22	2017-10-12	Genentech, Inc.	Ion exchange membrane chromatography
WO2013091903A1 (en)	2011-12-22	2013-06-27	Novo Nordisk A/S	Anti-crac channel antibodies
JP2015508994A (ja)	2011-12-30	2015-03-26	アッヴィ・インコーポレイテッド	Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
CA2862835A1 (en)	2012-01-13	2013-07-18	Genentech, Inc.	Biological markers for identifying patients for treatment with vegf antagonists
CA2861124A1 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
EP2819700B1 (de)	2012-02-27	2016-12-21	Universitat de Barcelona	Proteaseresistente verbindungen zur verwendung als shuttles durch die blut-hirn-schranke und shuttle-cargo-konstrukte
CN104334577A (zh)	2012-03-13	2015-02-04	霍夫曼-拉罗奇有限公司	治疗卵巢癌的联合疗法
CA2866753C (en)	2012-03-27	2020-09-22	Genentech, Inc.	Improved harvest operations for recombinant proteins
EP2830661A4 (de)	2012-03-30	2016-05-18	Hoffmann La Roche	Diagnostische verfahren und zusammensetzungen zur krebsbehandlung
ES2740749T3 (es)	2012-04-20	2020-02-06	Merus Nv	Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
WO2013170182A1 (en)	2012-05-11	2013-11-14	Synta Pharmaceuticals Corp.	Treating cancer with an hsp90 inhibitory compound
US10494440B2 (en)	2012-05-11	2019-12-03	Vaccinex, Inc.	Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CA2874144C (en)	2012-05-31	2023-12-19	Genentech, Inc.	Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
DE202013012825U1 (de)	2012-06-01	2020-02-06	Novartis Ag	Spritze
SG11201407537YA (en)	2012-06-08	2014-12-30	Hoffmann La Roche	Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
BR112014028368A2 (pt)	2012-06-27	2017-11-14	Hoffmann La Roche	método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
JOP20200175A1 (ar)	2012-07-03	2017-06-16	Novartis Ag	حقنة
EP2872534B1 (de)	2012-07-13	2018-08-08	Roche Glycart AG	Bispezifische anti-vegf-/anti-ang-2-antikörper und ihre verwendung bei der behandlung von vaskulären augenerkrankungen
RU2015104001A (ru)	2012-08-07	2016-09-27	Дженентек, Инк.	Комбинированная терапия для лечения глиобластомы
CN104662161A (zh)	2012-09-19	2015-05-27	弗·哈夫曼-拉罗切有限公司	用于防止正亮氨酸错误地掺入蛋白质中的方法和组合物
CA2889638A1 (en)	2012-10-31	2014-05-08	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a dll4 antagonist
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
JP2016500058A (ja)	2012-11-12	2016-01-07	レッドウッドバイオサイエンス，インコーポレイテッド	化合物および抱合体を生成するための方法
WO2014078733A1 (en)	2012-11-16	2014-05-22	The Regents Of The University Of California	Pictet-spengler ligation for protein chemical modification
US9310374B2 (en)	2012-11-16	2016-04-12	Redwood Bioscience, Inc.	Hydrazinyl-indole compounds and methods for producing a conjugate
SG11201503566QA (en)	2012-12-18	2015-09-29	Novartis Ag	Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014100095A1 (en)	2012-12-19	2014-06-26	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
AU2014205369B2 (en)	2013-01-11	2018-08-09	Massachusetts Eye And Ear Infirmary	CYP450 lipid metabolites reduce inflammation and angiogenesis
EP2951307B1 (de)	2013-02-04	2019-12-25	Vascular Biogenics Ltd.	Verfahren zur induzierung der empfänglichkeit für antiangiogenen wirkstoff
JP6408492B2 (ja)	2013-02-18	2018-10-17	ヴェジェニクスプロプライエタリーリミテッドＶｅｇｅｎｉｃｓＰｔｙＬｉｍｉｔｅｄ	リガンド結合分子およびその使用
MX365567B (es)	2013-03-13	2019-06-07	Genentech Inc	Formulaciones de anticuerpo.
EP2970459A2 (de)	2013-03-15	2016-01-20	AbbVie Inc.	Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
BR112015022529A2 (pt)	2013-03-15	2017-07-18	Genentech Inc	meios de cultura de células e processos de produção de anticorpo
US9707154B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TWI747803B (zh)	2013-04-29	2021-12-01	瑞士商赫孚孟拉羅股份公司	人類結合ｆｃｒｎ之經修飾抗體及使用方法
WO2014177459A2 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fc-receptor binding modified asymmetric antibodies and methods of use
SG10201703977UA (en)	2013-05-23	2017-06-29	Five Prime Therapeutics Inc	Methods of treating cancer
KR101541478B1 (ko) *	2013-05-31	2015-08-05	동아쏘시오홀딩스 주식회사	항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
SG10201902380SA (en)	2013-06-25	2019-04-29	Vaccinex Inc	Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
BR112016000546A2 (pt)	2013-07-12	2017-11-21	Ophthotech Corp	métodos para tratar ou prevenir condições oftalmológicas
EP3033436A1 (de)	2013-08-12	2016-06-22	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von komplementassoziierten erkrankungen
US10456470B2 (en)	2013-08-30	2019-10-29	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en)	2013-08-30	2020-04-14	Genentech, Inc.	Combination therapy for the treatment of glioblastoma
HUE052447T2 (hu)	2013-09-08	2021-04-28	Kodiak Sciences Inc	A VIII. tényezõs zwitterionos polimer konjugációk
NZ630881A (en)	2013-10-10	2016-03-31	Vaccinex Inc	Use of semaphorin-4d binding molecules for treatment of atherosclerosis
CA2922912A1 (en)	2013-10-11	2015-04-16	F. Hoffmann-La Roche Ag	Multispecific domain exchanged common variable light chain antibodies
NZ630892A (en)	2013-10-21	2016-03-31	Vaccinex Inc	Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3851118A1 (de)	2013-10-25	2021-07-21	Acceleron Pharma Inc.	Endoglinpeptide zur behandlung fibrotischer erkrankungen
US10568951B2 (en)	2013-11-18	2020-02-25	Formycon Ag	Pharmaceutical composition of an anti-VEGF antibody
CA3178867A1 (en)	2013-11-27	2015-06-04	Redwood Bioscience, Inc.	Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
TW201524998A (zh) *	2013-12-31	2015-07-01	Dev Center Biotechnology	抗ｖｅｇｆ抗體及其用途
RU2698969C2 (ru)	2014-01-15	2019-09-02	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с улучшенной способностью связываться с белком а
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
RU2692248C2 (ru)	2014-02-14	2019-06-24	Макродженикс, Инк.	Улучшенные способы лечения васкуляризированных злокачественных опухолей
ES2831014T3 (es)	2014-02-18	2021-06-07	Inst Nat Sante Rech Med	Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR
US10590455B2 (en)	2014-02-25	2020-03-17	Dr. Reddy's Laboratories Limited	Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
EP3116891B1 (de)	2014-03-10	2020-02-12	Richter Gedeon Nyrt.	Immunglobulinreinigung mit vorreinigungsschritten
CA2936962C (en)	2014-03-14	2024-03-05	Novartis Ag	Antibody molecules to lag-3 and uses thereof
MX2016012285A (es)	2014-03-24	2017-01-23	Genentech Inc	Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
SG11201608106PA (en)	2014-03-31	2016-10-28	Genentech Inc	Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
PE20161440A1 (es)	2014-05-01	2017-01-26	Genentech Inc	Variantes del anticuerpo anti-factor d y sus usos
RU2702748C2 (ru)	2014-05-12	2019-10-11	Формикон Аг	Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
US20170158776A1 (en)	2014-05-15	2017-06-08	Bristol-Myers Squibb Company	Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3151830A4 (de)	2014-06-06	2018-02-07	Redwood Bioscience, Inc.	Anti-her2-antikörper-maytansin-konjugate und verfahren zur verwendung davon
WO2015198240A2 (en)	2014-06-25	2015-12-30	Novartis Ag	Compositions and methods for long acting proteins
EP3160990A2 (de)	2014-06-25	2017-05-03	Novartis AG	Zusammensetzungen und verfahren für proteine mit langer wirkung
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
CA2953154C (en)	2014-07-09	2023-03-14	Genentech, Inc.	Ph adjustment to improve thaw recovery of cell banks
EP3169801A1 (de)	2014-07-14	2017-05-24	F. Hoffmann-La Roche AG	Diagnostische verfahren und zusammensetzungen zur behandlung von glioblastomen
CA2957717C (en)	2014-08-12	2021-10-19	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en)	2014-08-12	2017-08-03	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CN105330739B (zh) *	2014-08-12	2020-12-25	中美华世通生物医药科技（武汉）有限公司	与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途
WO2016040880A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
AU2015318001B2 (en)	2014-09-15	2021-03-25	Genentech, Inc.	Antibody formulations
CA2963281A1 (en)	2014-10-03	2016-04-07	Novartis Ag	Combination therapies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es)	2014-10-14	2023-11-03	Novartis Ag	Moléculas de anticuerpos contra PD-L1 y usos de las mismas
CN107208076A (zh)	2014-10-17	2017-09-26	科达制药	丁酰胆碱酯酶两性离子聚合物缀合物
WO2016065329A1 (en)	2014-10-24	2016-04-28	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
DK3212233T3 (da)	2014-10-31	2020-07-27	Oncomed Pharm Inc	Kombinationsterapi til behandling af sygdom
BR112017009728A2 (pt)	2014-11-10	2018-02-06	Genentech, Inc.	anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EP3227332B1 (de)	2014-12-03	2019-11-06	F.Hoffmann-La Roche Ag	Multispezifische antikörper
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
LT3230316T (lt)	2014-12-11	2022-02-10	Bayer Healthcare Llc	Gydymas su amžiumi susijusios geltonosios dėmės degeneracijos su mažu aktyvios choroidinės neovaskuliarizacijos pažeidimu
US20170340733A1 (en)	2014-12-19	2017-11-30	Novartis Ag	Combination therapies
WO2016106340A2 (en)	2014-12-23	2016-06-30	Genentech, Inc.	Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
CN107206080B (zh)	2015-01-28	2022-07-08	辉瑞公司	稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
SG11201707276PA (en)	2015-03-09	2017-10-30	Intekrin Therapeutics Inc	Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
SI3286315T1 (sl)	2015-04-24	2021-09-30	F. Hoffmann-La Roche Ag	Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
US20180155429A1 (en)	2015-05-28	2018-06-07	Bristol-Myers Squibb Company	Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en)	2015-05-29	2016-12-08	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
MX2017015937A (es)	2015-06-08	2018-12-11	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3322731B1 (de)	2015-07-14	2021-01-13	Bristol-Myers Squibb Company	Verfahren zur behandlung von krebs mit immune checkpoint-hemmer; antikörper, bindet an programmierter zelltod-1-rezeptor (pd-1) oder programmierte tod ligand 1 (pd-l1)
ES2828694T3 (es)	2015-07-29	2021-05-27	Allergan Inc	Anticuerpos sólo de cadena pesada frente a ANG-2
EP3328418A1 (de)	2015-07-29	2018-06-06	Novartis AG	Kombinationstherapien mit antikörpermolekülen gegen pd-1
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
HU231463B1 (hu)	2015-08-04	2024-01-28	Richter Gedeon Nyrt.	Módszer rekombináns proteinek galaktóz tartalmának növelésére
CA2992788A1 (en)	2015-08-14	2017-02-23	Allergan, Inc.	Heavy chain only antibodies to pdgf
CA2987644A1 (en) *	2015-08-21	2017-03-02	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
IL257531B2 (en)	2015-09-17	2023-04-01	Immunogen Inc	Medicinal compositions containing anti-folr1 immunoconjugates
WO2017046140A1 (en)	2015-09-18	2017-03-23	Bayer Pharma Aktiengesellschaft	Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017050793A1 (en)	2015-09-22	2017-03-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
CN109071644B (zh)	2015-09-23	2023-09-19	昂考梅德药品有限公司	治疗癌症的方法和组合物
RU2763916C2 (ru)	2015-09-23	2022-01-11	Дженентек, Инк.	Оптимизированные варианты анти-vegf антител
WO2017055321A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055322A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of neutrophils in a tissue sample
WO2017055319A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of b cells in a tissue sample
WO2017055326A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055327A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055325A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of nk cells in a tissue sample
WO2017055324A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055320A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017064121A1 (en)	2015-10-13	2017-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CA3088612C (en)	2015-10-30	2022-04-12	Genentech, Inc.	Anti-htra1 antibodies and methods of use thereof
KR20180069906A (ko)	2015-10-30	2018-06-25	제넨테크, 인크.	항-인자 d 항체 제제
TW201730211A (zh)	2015-10-30	2017-09-01	建南德克公司	抗因子d抗體及結合物
US10654932B2 (en)	2015-10-30	2020-05-19	Genentech, Inc.	Anti-factor D antibody variant conjugates and uses thereof
JP2019500892A (ja)	2015-11-03	2019-01-17	ヤンセンバイオテツク，インコーポレーテツド	Ｔｉｍ−３に特異的に結合する抗体及びその使用
US20190209697A1 (en)	2015-11-05	2019-07-11	The Regents Of The University Of California	Cells labelled with lipid conjugates and methods of use thereof
IL259186B2 (en)	2015-11-09	2023-03-01	Scherer Technologies Llc R P	Anti-cd22-maytensin antibody conjugates and methods of using them
MX2018006171A (es)	2015-11-18	2018-12-19	Formycon Ag	Jeringa de plastico precargada que contiene un antagonista de vegf.
CA3005132A1 (en)	2015-11-18	2017-05-26	Sio2 Medical Products, Inc.	Coated syringe for ophthalmic formulations containing a vegf antagonist
BR112018009953B1 (pt)	2015-11-18	2024-03-05	Formycon Ag	Seringa farmacêutica pré-preenchida esterilizada, e, kit
CN108474039B (zh)	2015-12-03	2022-06-07	雷杰纳荣制药公司	抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
US20180371093A1 (en)	2015-12-17	2018-12-27	Novartis Ag	Antibody molecules to pd-1 and uses thereof
EP3397276A4 (de)	2015-12-30	2019-12-18	Kodiak Sciences Inc.	Antikörper und konjugate davon
AU2017213103B2 (en)	2016-01-26	2022-08-11	Formycon Ag	Liquid formulation of a VEGF antagonist
CN109069638B (zh)	2016-03-24	2022-03-29	璟尚生物制药公司	用于癌症治疗的三特异性抑制剂
CA3019373A1 (en)	2016-03-29	2017-10-05	Geltor, Inc.	Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
PL3443350T3 (pl)	2016-04-15	2021-05-31	F. Hoffmann-La Roche Ag	Sposoby monitorowania i leczenia nowotworu
EP3443120A2 (de)	2016-04-15	2019-02-20	H. Hoffnabb-La Roche Ag	Verfahren zur überwachung und behandlung von krebs
PT4019019T (pt)	2016-05-20	2024-05-13	Biohaven Therapeutics Ltd	Utilização de riluzol, profármacos de riluzol ou análogos de riluzol com imunoterapêuticas para tratar o cancro
EP3482205A1 (de)	2016-07-08	2019-05-15	H. Hoffnabb-La Roche Ag	Verwendung des humanen epididymisproteins 4 (he4) zur beurteilung des ansprechens auf eine behandlung von muc-16-positivem krebs
WO2018009939A1 (en)	2016-07-08	2018-01-11	Genentech, Inc.	Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018011166A2 (en)	2016-07-12	2018-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
KR20190031246A (ko)	2016-07-20	2019-03-25	에르피오 세러퓨틱스 인코포레이티드	VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
WO2018018613A1 (zh)	2016-07-29	2018-02-01	广东东阳光药业有限公司	一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) *	2016-07-29	2016-12-14	广东东阳光药业有限公司	一种提高抗体纯度的细胞培养基和培养方法
AU2017311585A1 (en)	2016-08-12	2019-02-28	Genentech, Inc.	Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
IL264961B2 (en)	2016-08-23	2025-02-01	Medimmune Ltd	Antibodies against VEGF–A and their uses
EP3527225A4 (de)	2016-10-12	2020-06-10	Daiichi Sankyo Company, Limited	Zusammensetzung mit anti-robo4-antikörper und anderen mitteln
US11192925B2 (en)	2016-10-19	2021-12-07	Adverum Biotechnologies, Inc.	Modified AAV capsids and uses thereof
CN109071656B (zh)	2017-01-05	2021-05-18	璟尚生物制药公司	检查点调节物拮抗剂
US10350266B2 (en)	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
JP2020505438A (ja)	2017-01-10	2020-02-20	ノダス・セラピューティクスＮｏｄｕｓＴｈｅｒａｐｅｕｔｉｃｓ	インテグリン結合性ポリペプチド−Ｆｃ融合タンパク質および免疫調節物質を用いる併用がん治療法
WO2018160841A1 (en)	2017-03-01	2018-09-07	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
EP3601332A1 (de) *	2017-03-24	2020-02-05	Council of Scientific and Industrial Research	Verfahren zur reinigung rekombinanter antikörperfragmente
KR20200036808A (ko)	2017-04-03	2020-04-07	코히러스 바이오사이언시스, 인크.	진행성 핵상 마비 치료를 위한 PPARγ 작용제
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
MX2019013750A (es)	2017-05-19	2020-07-20	Council Scient Ind Res	Un metodo para producir ranibizumab humanizado recombinante replegado.
US20200171244A1 (en)	2017-05-24	2020-06-04	Sio2 Medical Products, Inc.	Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (de)	2017-05-24	2020-04-08	Formycon AG	Sterilisierbare vorgefüllte pharmazeutische verpackungen mit einer flüssigen formulierung eines vegf-antagonisten
TW201904610A (zh)	2017-06-14	2019-02-01	德商拜耳製藥公司	用於治療新生血管型青光眼之非抗體vegf拮抗劑
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
MA49457A (fr)	2017-06-22	2020-04-29	Novartis Ag	Molécules d'anticorps se liant à cd73 et leurs utilisations
JP7163288B2 (ja)	2017-07-04	2022-10-31	第一三共株式会社	視細胞変性を伴う網膜変性疾患用薬
WO2019020777A1 (en)	2017-07-26	2019-01-31	Formycon Ag	LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019057946A1 (en)	2017-09-25	2019-03-28	F. Hoffmann-La Roche Ag	MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
CN111356480A (zh)	2017-10-20	2020-06-30	脉管生物生长有限公司	用于抗血管生成剂疗法的诊断方法
US20210071149A1 (en)	2017-12-19	2021-03-11	Akouos, Inc.	Aav-mediated delivery of therapeutic antibodies to the inner ear
EP3731865A1 (de)	2017-12-29	2020-11-04	F. Hoffmann-La Roche AG	Verfahren zur verbesserung der vegf-rezeptor-blockierenden selektivität eines anti-vegf-antikörpers
CN110283248B (zh) *	2018-01-05	2020-07-28	百奥泰生物制药股份有限公司	一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
KR20200119274A (ko)	2018-02-06	2020-10-19	에프. 호프만-라 로슈 아게	안과 질환의 치료
EP3758737A4 (de)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	Il-6-antikörper und fusionskonstrukte und konjugate davon
EP3762421A2 (de)	2018-03-09	2021-01-13	Agenus Inc.	Anti-cd73-antikörper und verfahren zu ihrer verwendung
CN111989095A (zh)	2018-04-16	2020-11-24	上海岸阔医药科技有限公司	预防或治疗肿瘤疗法副作用的方法
BR112020022610A2 (pt)	2018-05-10	2021-02-09	Regeneron Pharmaceuticals, Inc.	proteína de fusão de receptor de vegf de alta concentração que contém formulações
KR20210015902A (ko)	2018-05-24	2021-02-10	얀센 바이오테크 인코포레이티드	Psma 결합제 및 이의 용도
US11519020B2 (en)	2018-05-25	2022-12-06	Regeneron Pharmaceuticals, Inc.	Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2019229116A1 (en)	2018-05-31	2019-12-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
WO2020006509A1 (en)	2018-06-29	2020-01-02	Gensun Biopharma, Inc.	Antitumor antagonists
AU2019299358A1 (en)	2018-07-03	2021-02-18	Bristol-Myers Squibb Company	Methods of producing recombinant proteins
GB201811410D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	OX40 Binding molecules
CN109053895B (zh)	2018-08-30	2020-06-09	中山康方生物医药有限公司	抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP2022502367A (ja)	2018-09-24	2022-01-11	エアーピオファーマシューティカルズ，インコーポレイテッド	ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
WO2020076776A1 (en)	2018-10-10	2020-04-16	Boehringer Ingelheim International Gmbh	Method for membrane gas transfer in high density bioreactor culture
JP2022512744A (ja)	2018-10-18	2022-02-07	ジェネンテック，インコーポレイテッド	肉腫様腎臓がんのための診断および治療方法
HU231514B1 (hu)	2018-11-07	2024-07-28	Richter Gedeon Nyrt.	Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
CN109134651B (zh) *	2018-12-03	2019-02-22	上海复宏汉霖生物技术股份有限公司	一种抗vegf的单克隆抗体及其制备方法和应用
WO2020118043A1 (en)	2018-12-07	2020-06-11	Coherus Biosciences, Inc.	Methods for producing recombinant proteins
KR20210105890A (ko)	2018-12-17	2021-08-27	레비토프 리미티드	트윈 면역 세포 인게이저
JP2022524321A (ja)	2019-03-13	2022-05-02	バスキュラーバイオジェニックスリミテッド	抗腫瘍療法の方法
AU2020254582A1 (en)	2019-04-01	2021-09-30	Genentech, Inc.	Compositions and methods for stabilizing protein-containing formulations
HU231498B1 (hu)	2019-04-04	2024-05-28	Richter Gedeon Nyrt	Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
SG11202111349QA (en)	2019-04-12	2021-11-29	Geltor Inc	Recombinant elastin and production thereof
JP2022529985A (ja)	2019-04-19	2022-06-27	ヤンセンバイオテツク，インコーポレーテツド	抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法
TWI862583B (zh)	2019-04-26	2024-11-21	美商愛德維仁生物科技公司	用於玻璃體內遞送之變異體aav蛋白殼
CA3133821A1 (en)	2019-05-03	2020-11-12	Genentech, Inc.	Methods of treating cancer with an anti-pd-l1 antibody
US20220211847A1 (en)	2019-05-06	2022-07-07	Medimmune Limited	Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
US10851157B2 (en)	2019-07-01	2020-12-01	Gensun Biopharma, Inc.	Antagonists targeting the TGF-β pathway
KR20220039777A (ko)	2019-08-01	2022-03-29	브리스톨-마이어스 스큅 컴퍼니	유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
EP4031578A1 (de)	2019-09-18	2022-07-27	Novartis AG	Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
WO2021072265A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
WO2021072182A1 (en)	2019-10-11	2021-04-15	Coherus Biosciences, Inc.	Methods for producing ranibizumab
US20240092883A1 (en)	2019-10-11	2024-03-21	Coherus Biosciences, Inc.	Methods of purifying ranibizumab or a ranibizumab variant
WO2021100034A1 (en)	2019-11-19	2021-05-27	Protalix Ltd.	Removal of constructs from transformed cells
CN112830972A (zh)	2019-11-25	2021-05-25	中山康方生物医药有限公司	抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途
EP4118235A1 (de)	2020-03-11	2023-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur bestimmung, ob ein patient eine zentrale seröse chorioretinopathie hat oder gefährdet ist, eine solche zu haben
CA3174680A1 (en)	2020-03-13	2021-09-16	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
CA3172449A1 (en)	2020-03-27	2021-09-30	Erik Hans MANTING	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023520515A (ja)	2020-04-03	2023-05-17	ジェネンテック，インコーポレイテッド	がんに対する治療方法及び診断方法
CN116133679A (zh)	2020-06-30	2023-05-16	门德斯有限公司	白血病衍生细胞在卵巢癌疫苗中的用途
IL299586A (en)	2020-07-16	2023-03-01	Novartis Ag	Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
CN114106190B (zh) *	2020-08-31	2025-04-08	普米斯生物技术(珠海)有限公司	一种抗vegf/pd-l1双特异性抗体及其用途
WO2022066595A1 (en)	2020-09-22	2022-03-31	Bristol-Myers Squibb Company	Methods for producing therapeutic proteins
EP4225902A1 (de)	2020-10-05	2023-08-16	Protalix Ltd.	Würfelförmige knockout-pflanzenzellen
TW202228790A (zh)	2020-10-15	2022-08-01	美商建南德克公司	用於長效經眼遞送之非共價蛋白質－玻尿酸結合物
US12016862B2 (en)	2020-11-13	2024-06-25	Genentech, Inc	Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
CA3201005A1 (en)	2020-11-20	2022-05-27	R.P. Scherer Technologies, Llc	Glycoside dual-cleavage linkers for antibody-drug conjugates
CR20230228A (es)	2020-12-01	2023-07-18	Akouos Inc	Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
WO2022157715A1 (en)	2021-01-22	2022-07-28	Dcprime B.V.	Methods of tumor vaccination
WO2022162518A2 (en)	2021-01-28	2022-08-04	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
EP4304633A1 (de)	2021-03-12	2024-01-17	Mendus B.V.	Verfahren zur impfung und verwendung von cd47-blockade
KR20230156910A (ko)	2021-03-12	2023-11-15	아케소 바이오파마, 인크.	항-pd-1-항-vegfa 이중특이적 항체를 함유하는 약학적 조합 및 이의 용도
WO2022232503A1 (en)	2021-04-30	2022-11-03	Genentech, Inc.	Therapeutic and diagnostic methods and compositions for cancer
CN117157309A (zh)	2021-05-28	2023-12-01	上海瑞宏迪医药有限公司	衣壳变异的重组腺相关病毒及其应用
US20240279324A1 (en)	2021-06-03	2024-08-22	Gensun Biopharma Inc.	Multispecific antagonists
WO2023279092A2 (en)	2021-07-02	2023-01-05	Genentech, Inc.	Methods and compositions for treating cancer
AU2022317820A1 (en)	2021-07-28	2023-12-14	F. Hoffmann-La Roche Ag	Methods and compositions for treating cancer
US20250115666A1 (en)	2021-08-05	2025-04-10	Bristol-Myers Squibb Company	Cell culture methods for producing therapeutic proteins
AU2022327397A1 (en)	2021-08-13	2024-03-14	Innovent Biologics (Suzhou) Co., Ltd.	Anti-vegf a and -vegf c bispecific antibody and use thereof
EP4145456A1 (de)	2021-09-06	2023-03-08	Bayer AG	Vorhersage einer änderung in zusammenhang mit einer makulaflüssigkeit
WO2023049687A1 (en)	2021-09-21	2023-03-30	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
JPWO2023144973A1 (de)	2022-01-27	2023-08-03
JP2025502545A (ja)	2022-01-28	2025-01-24	オンクオリティファーマシューティカルズチャイナリミテッド	抗腫瘍剤の投与に伴う疾患もしくは病気を予防又は治療する方法
TW202342525A (zh)	2022-02-02	2023-11-01	美商阿科奧斯公司	用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
WO2023155905A1 (zh)	2022-02-21	2023-08-24	上海岸阔医药科技有限公司	化合物及其用途
WO2024040175A1 (en)	2022-08-18	2024-02-22	Pulmatrix Operating Company, Inc.	Methods for treating cancer using inhaled angiogenesis inhibitor
CN117679505A (zh)	2022-09-09	2024-03-12	中山康方生物医药有限公司	药物组合及用途
WO2024186635A2 (en)	2023-03-03	2024-09-12	Celldex Therapeutics, Inc.	Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
WO1981001145A1 (en)	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
JPS6289971A (ja) *	1985-06-13	1987-04-24	Toray Ind Inc	静電潜像用液体現像剤
EP0206448B1 (de)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en)	1987-03-09	1987-04-15	Carlton Med Prod	Drug delivery systems
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ATE135397T1 (de)	1988-09-23	1996-03-15	Cetus Oncology Corp	Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
ATE189526T1 (de) *	1988-10-28	2000-02-15	Genentech Inc	Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5147638A (en)	1988-12-30	1992-09-15	Oklahoma Medical Research Foundation	Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (de)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
SK281143B6 (sk) *	1991-03-06	2000-12-11	Merck Patent Gesellschaft Mit Beschr�Nkter Haftung	Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
EP0580737B1 (de)	1991-04-10	2004-06-16	The Scripps Research Institute	Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
WO1992022653A1 (en) *	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
WO1993016177A1 (en)	1992-02-11	1993-08-19	Cell Genesys, Inc.	Homogenotization of gene-targeting events
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
ES2360641T3 (es) *	1992-10-28	2011-06-07	Genentech, Inc.	Uso de antagonistas del factor de crecimiento endotelial vascular.
NZ258392A (en)	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5534615A (en)	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) *	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
KR100816621B1 (ko) *	1997-04-07	2008-03-24	제넨테크, 인크.	항-ｖｅｇｆ 항체
EP3260468A1 (de) *	1997-04-07	2017-12-27	Genentech, Inc.	Anti-vegf-antikörper
US20020032315A1 (en) *	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies

1998
- 1998-04-03 KR KR1020077027778A patent/KR100816621B1/ko not_active Expired - Lifetime
- 1998-04-03 SI SI9830758T patent/SI1325932T1/xx unknown
- 1998-04-03 WO PCT/US1998/006604 patent/WO1998045331A2/en active IP Right Grant
- 1998-04-03 DE DE200712000021 patent/DE122007000021I1/de active Pending
- 1998-04-03 EP EP03004199A patent/EP1325932B9/de not_active Expired - Lifetime
- 1998-04-03 CA CA002286330A patent/CA2286330C/en not_active Expired - Lifetime
- 1998-04-03 DK DK03004199T patent/DK1325932T5/da active
- 1998-04-03 KR KR1020077027779A patent/KR100870353B1/ko not_active Expired - Lifetime
- 1998-04-03 ES ES03004199T patent/ES2236634T3/es not_active Expired - Lifetime
- 1998-04-03 NZ NZ500078A patent/NZ500078A/en not_active IP Right Cessation
- 1998-04-03 TR TR1999/03123T patent/TR199903123T2/xx unknown
- 1998-04-03 JP JP54292298A patent/JP3957765B2/ja not_active Expired - Lifetime
- 1998-04-03 DE DE200512000026 patent/DE122005000026I1/de active Pending
- 1998-04-03 EP EP98917991A patent/EP0973804B1/de not_active Expired - Lifetime
- 1998-04-03 ES ES98917991T patent/ES2273415T3/es not_active Expired - Lifetime
- 1998-04-03 DK DK98917991T patent/DK0973804T3/da active
- 1998-04-03 BR BRPI9809387A patent/BRPI9809387B8/pt not_active IP Right Cessation
- 1998-04-03 EP EP06075078A patent/EP1650220B1/de not_active Expired - Lifetime
- 1998-04-03 AT AT98917991T patent/ATE349470T1/de active
- 1998-04-03 AT AT03004199T patent/ATE293640T1/de active
- 1998-04-03 DE DE69836729T patent/DE69836729T2/de not_active Expired - Lifetime
- 1998-04-03 IL IL13224098A patent/IL132240A0/xx active IP Right Grant
- 1998-04-03 PT PT03004199T patent/PT1325932E/pt unknown
- 1998-04-03 CN CNB988059142A patent/CN100480269C/zh not_active Expired - Lifetime
- 1998-04-03 EP EP06024703A patent/EP1787999B1/de not_active Expired - Lifetime
- 1998-04-03 AU AU71007/98A patent/AU743758B2/en not_active Expired
- 1998-04-03 DE DE69829891T patent/DE69829891T2/de not_active Expired - Lifetime
1999
- 1999-10-06 NO NO19994869A patent/NO324264B1/no not_active IP Right Cessation
2000
- 2000-05-04 HK HK06106660A patent/HK1084402A1/xx not_active IP Right Cessation
- 2000-05-04 HK HK00102696A patent/HK1023577A1/xx not_active IP Right Cessation
- 2000-11-27 US US09/723,752 patent/US7060269B1/en not_active Expired - Lifetime
2004
- 2004-10-26 US US10/974,591 patent/US7297334B2/en not_active Expired - Fee Related
2005
- 2005-04-20 FR FR05C0020C patent/FR05C0020I2/fr active Active
- 2005-04-20 NL NL300193C patent/NL300193I2/nl unknown
- 2005-04-20 LT LTPA2005005C patent/LTPA2005005I1/lt unknown
- 2005-04-20 LU LU91167C patent/LU91167I2/fr unknown
- 2005-04-21 CY CY2005008C patent/CY2005008I2/el unknown
- 2005-05-25 DE DE200512000050 patent/DE122005000050I1/de active Pending
2007
- 2007-02-28 LU LU91320C patent/LU91320I2/fr unknown
- 2007-03-07 FR FR07C0017C patent/FR07C0017I2/fr active Active
- 2007-03-14 CY CY20071100358T patent/CY1106382T1/el unknown
- 2007-03-26 NL NL300278C patent/NL300278I2/nl unknown
- 2007-04-05 CY CY200700012C patent/CY2007012I1/el unknown
- 2007-12-20 NO NO2007014C patent/NO2007014I2/no unknown
- 2007-12-20 NO NO2007015C patent/NO2007015I1/no not_active IP Right Cessation
2009
- 2009-12-24 GE GEAP200911617A patent/GEP20105118B/en unknown

Also Published As

Publication number	Publication date
EP1325932A2 (de)	2003-07-09
US20050112126A1 (en)	2005-05-26
NZ500078A (en)	2001-10-26
AU743758B2 (en)	2002-02-07
KR20080003452A (ko)	2008-01-07
WO1998045331A3 (en)	1998-12-03
CY2007012I2 (el)	2009-11-04
CA2286330A1 (en)	1998-10-15
KR100816621B1 (ko)	2008-03-24
TR199903123T2 (xx)	2000-05-22
NO2007014I1 (no)	2008-01-14
LTPA2005005I1 (lt)	2017-11-27
CY2005008I1 (el)	2009-11-04
IL132240A0 (en)	2001-03-19
CN100480269C (zh)	2009-04-22
FR05C0020I2 (fr)	2008-05-09
SI1325932T1 (de)	2005-08-31
EP1325932B9 (de)	2006-07-19
HK1084402A1 (en)	2006-07-28
DE69836729T2 (de)	2007-12-13
LU91320I2 (fr)	2007-04-30
ATE349470T1 (de)	2007-01-15
JP3957765B2 (ja)	2007-08-15
DK1325932T5 (da)	2005-10-03
NO994869L (no)	1999-12-06
EP1325932A3 (de)	2003-10-29
GEP20105118B (en)	2010-11-25
HK1023577A1 (en)	2000-09-15
EP1650220A3 (de)	2006-05-03
DE122005000050I1 (de)	2005-12-29
NL300278I1 (nl)	2007-06-01
LU91320I9 (de)	2018-12-31
EP1787999B1 (de)	2010-08-04
FR07C0017I2 (fr)	2008-05-09
EP1787999A1 (de)	2007-05-23
NO324264B1 (no)	2007-09-17
NL300193I1 (nl)	2005-07-01
DE69829891D1 (de)	2005-05-25
CY2005008I2 (el)	2017-11-14
ATE293640T1 (de)	2005-05-15
WO1998045331A2 (en)	1998-10-15
EP0973804A2 (de)	2000-01-26
BRPI9809387B1 (pt)	2016-11-22
NO2007015I1 (no)	2008-01-14
US7060269B1 (en)	2006-06-13
FR05C0020I1 (de)	2005-05-27
CY1106382T1 (el)	2010-07-28
NO994869D0 (no)	1999-10-06
LU91167I2 (fr)	2005-06-20
NL300278I2 (nl)	2007-10-01
JP2001509817A (ja)	2001-07-24
KR100870353B1 (ko)	2008-11-25
US7297334B2 (en)	2007-11-20
BR9809387A (pt)	2001-09-11
FR07C0017I1 (fr)	2007-04-27
EP1650220A2 (de)	2006-04-26
BRPI9809387B8 (pt)	2021-05-25
CY2007012I1 (el)	2009-11-04
NO2007014I2 (no)	2011-02-21
ES2236634T3 (es)	2005-07-16
NL300193I2 (nl)	2005-10-03
KR20080003453A (ko)	2008-01-07
DK0973804T3 (da)	2007-05-07
DK1325932T3 (da)	2005-05-30
PT1325932E (pt)	2005-06-30
DE122005000026I1 (de)	2005-08-04
AU7100798A (en)	1998-10-30
DE122007000021I1 (de)	2007-05-24
NO2007015I2 (de)	2011-11-28
CA2286330C (en)	2008-06-10
EP1325932B1 (de)	2005-04-20
EP1650220B1 (de)	2007-09-05
DE69829891T2 (de)	2005-10-06
CN1259962A (zh)	2000-07-12
ES2273415T3 (es)	2007-05-01
EP0973804B1 (de)	2006-12-27

Publication	Publication Date	Title
NO2019045I1 (no)	2019-12-11	Ranibizumab - Forlenget SPC
DE69836729D1 (de)	2007-02-08	Anti-vefg antibodies

Legal Events

Date	Code	Title	Description
2017-02-14	R067	Examining division decision granting supplementary protection certificate	Free format text: PRODUCT NAME: RANIBIZUMAB; REGISTRATION NO/DATE: EU/1/06/374/001 20070122 Spc suppl protection certif: 122007000021 Filing date: 20070305 Expiry date: 20180404 Extension date: 20220124
2017-03-18	R069	Supplementary protection certificate granted	Free format text: PRODUCT NAME: RANIBIZUMAB; REGISTRATION NO/DATE: EU/1/06/374/001 20070122 Spc suppl protection certif: 122007000021 Filing date: 20070305 Expiry date: 20180404 Extension date: 20220124

Date

Code

Title

Description

2017-02-14

R067

Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: RANIBIZUMAB; REGISTRATION NO/DATE: EU/1/06/374/001 20070122

Spc suppl protection certif: 122007000021

Filing date: 20070305

Expiry date: 20180404

Extension date: 20220124

2017-03-18

R069

Supplementary protection certificate granted